10-75020544-C-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_012330.4(KAT6B):c.2630-38C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0416 in 1,421,902 control chromosomes in the GnomAD database, including 3,289 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.030 ( 232 hom., cov: 32)
Exomes 𝑓: 0.043 ( 3057 hom. )
Consequence
KAT6B
NM_012330.4 intron
NM_012330.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.103
Publications
3 publications found
Genes affected
KAT6B (HGNC:17582): (lysine acetyltransferase 6B) The protein encoded by this gene is a histone acetyltransferase and component of the MOZ/MORF protein complex. In addition to its acetyltransferase activity, the encoded protein has transcriptional activation activity in its N-terminal end and transcriptional repression activity in its C-terminal end. This protein is necessary for RUNX2-dependent transcriptional activation and could be involved in brain development. Mutations have been found in patients with genitopatellar syndrome. A translocation of this gene and the CREBBP gene results in acute myeloid leukemias. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2012]
KAT6B Gene-Disease associations (from GenCC):
- blepharophimosis - intellectual disability syndrome, SBBYS typeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Orphanet
- genitopatellar syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P
- KAT6B-related multiple congenital anomalies syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- RASopathyInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BP6
Variant 10-75020544-C-T is Benign according to our data. Variant chr10-75020544-C-T is described in ClinVar as Benign. ClinVar VariationId is 1250408.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.235 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0295 AC: 4495AN: 152186Hom.: 232 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
4495
AN:
152186
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.0544 AC: 13459AN: 247462 AF XY: 0.0638 show subpopulations
GnomAD2 exomes
AF:
AC:
13459
AN:
247462
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0430 AC: 54656AN: 1269598Hom.: 3057 Cov.: 18 AF XY: 0.0492 AC XY: 31534AN XY: 641466 show subpopulations
GnomAD4 exome
AF:
AC:
54656
AN:
1269598
Hom.:
Cov.:
18
AF XY:
AC XY:
31534
AN XY:
641466
show subpopulations
African (AFR)
AF:
AC:
148
AN:
29616
American (AMR)
AF:
AC:
723
AN:
44426
Ashkenazi Jewish (ASJ)
AF:
AC:
1087
AN:
24868
East Asian (EAS)
AF:
AC:
2697
AN:
38752
South Asian (SAS)
AF:
AC:
18891
AN:
82174
European-Finnish (FIN)
AF:
AC:
1078
AN:
52848
Middle Eastern (MID)
AF:
AC:
310
AN:
5382
European-Non Finnish (NFE)
AF:
AC:
27263
AN:
937568
Other (OTH)
AF:
AC:
2459
AN:
53964
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
2785
5570
8355
11140
13925
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
1156
2312
3468
4624
5780
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.0295 AC: 4496AN: 152304Hom.: 232 Cov.: 32 AF XY: 0.0331 AC XY: 2465AN XY: 74466 show subpopulations
GnomAD4 genome
AF:
AC:
4496
AN:
152304
Hom.:
Cov.:
32
AF XY:
AC XY:
2465
AN XY:
74466
show subpopulations
African (AFR)
AF:
AC:
244
AN:
41576
American (AMR)
AF:
AC:
315
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
AC:
155
AN:
3468
East Asian (EAS)
AF:
AC:
339
AN:
5186
South Asian (SAS)
AF:
AC:
1185
AN:
4812
European-Finnish (FIN)
AF:
AC:
229
AN:
10610
Middle Eastern (MID)
AF:
AC:
14
AN:
294
European-Non Finnish (NFE)
AF:
AC:
1960
AN:
68022
Other (OTH)
AF:
AC:
54
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
204
408
611
815
1019
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
74
148
222
296
370
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
493
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jun 26, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.